In a report released on August 1, David Martin PhD from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $11.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Martin PhD has given his Buy rating due to a combination of factors including Aurinia Pharmaceuticals’ impressive financial performance and future prospects. The company recently reported second-quarter results for 2025 that exceeded expectations, particularly with the robust sales of their Lupkynis product. This strong performance led to an increase in the company’s revenue guidance from the previous range of $250M-$260M to a new range of $260M-$270M.
Additionally, the sales of Lupkynis showed a significant year-over-year growth of 21% and an 11% increase quarter-over-quarter. This positive financial trajectory, coupled with the anticipation of the upcoming AUR200 indication reveal, supports the optimistic outlook for Aurinia Pharmaceuticals, justifying the Buy rating by David Martin PhD.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $12.00 price target.